RT Journal Article
SR Electronic
T1 Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer – Relationship with Clinical Outcome
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1153
OP 1161
VO 34
IS 3
A1 PATRIZIA FERRONI
A1 MARIO ROSELLI
A1 ILARIA PORTARENA
A1 VINCENZO FORMICA
A1 SILVIA RIONDINO
A1 FRANCESCA LA FARINA
A1 LEOPOLDO COSTARELLI
A1 ANTONIA MELINO
A1 GIOIA MASSIMIANI
A1 FRANCESCO CAVALIERE
A1 RAFFAELE PALMIROTTA
A1 FIORELLA GUADAGNI
YR 2014
UL http://ar.iiarjournals.org/content/34/3/1153.abstract
AB Background: Signaling pathways triggered by increased thrombin or plasminogen activator inhibitor-1 (PAI-1) expression drastically alter the tumor microenvironment, contributing to an adverse outcome. This study aimed to evaluate the prognostic value of coagulation/fibrinolytic activities in breast cancer (BC). Materials and Methods: Coagulation/fibrinolytic activities were investigated in 187 patients with breast cancer, with respect to possible associations with clinicopathological features and survival outcomes. Results: Levels of plasma PAI-1 (p<0.001), D-dimer (p=0.037) and activated protein C-dependent thrombin generation (p=0.003) were higher in women with breast cancer compared to 187 healthy women. PAI-1 directly correlated with D-dimer levels (p=0.009) and Ki67 expression (p=0.027), which were both predictors of elevated PAI-1 levels at multivariate regression analysis. Cox analysis demonstrated that an elevated plasma PAI-1 level had a negative prognostic impact in terms of relapse-free (hazard ratio=2.5, p=0.021) and overall survival (hazard ratio=2.7, p=0.002). Conclusion: Determination of plasma PAI-1 levels might provide important prognostic information in risk stratification and survival outcomes for patients with breast cancer.